InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

- Current share price for CUV : $8.100

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$408 Expansion of global porphyria programs 1 May 2023 9:09AM $20.220 $8.100 fallen by 59.94%
$408 CLINUVEL Newsletter II - April 2023 5 Apr 2023 9:09AM $19.000 $8.100 fallen by 57.37%
$408 Investor Presentation - NYC Nasdaq Event 30 Mar 2023 9:11AM $18.500 $8.100 fallen by 56.22%
$408 Technical Note - CUV803 Study and AIS 20 Mar 2023 11:52AM $20.010 $8.100 fallen by 59.52%
$408 First stroke patient treated with PRENUMBRA Instant 20 Mar 2023 9:00AM $20.320 $8.100 fallen by 60.14%
$408 DNA Repair data presented at AAD Meeting 17 Mar 2023 9:14AM $19.460 $8.100 fallen by 58.38%
$408 Statement on Silicon Valley Bank 13 Mar 2023 9:03AM $19.050 $8.100 fallen by 57.48%
$408 Proposed issue of securities - CUV 10 Mar 2023 2:43PM $19.110 $8.100 fallen by 57.61%
$408 Commercial Update SCENESSE 9 Mar 2023 10:43AM $19.660 $8.100 fallen by 58.80%
$408 Relief from Quarterly Reporting 2 Mar 2023 12:01PM $19.880 $8.100 fallen by 59.26%
$408 CLINUVEL launches first dermatocosmetic product 1 Mar 2023 9:44AM $19.090 $8.100 fallen by 57.57%
$408 Proposed issue of securities - CUV 28 Feb 2023 10:00AM $19.110 $8.100 fallen by 57.61%
$408 Global SCENESSE demand drives increased revenues, earnings 24 Feb 2023 9:41AM $24.050 $8.100 fallen by 66.32%
$408 CUV Appendix 4D Half Year Report 24 Feb 2023 9:36AM $24.050 $8.100 fallen by 66.32%
$408 PRENUMBRA formulation completed for clinical trial use 15 Feb 2023 9:27AM $23.600 $8.100 fallen by 65.68%
$408 Chair's Letter 9 Feb 2023 10:47AM $24.140 $8.100 fallen by 66.45%
$408 Technical note - CUV151 results 2 Feb 2023 10:34AM $24.150 $8.100 fallen by 66.46%
$408 Afamelanotide reduces UV skin damage in a healthy population 2 Feb 2023 10:34AM $24.150 $8.100 fallen by 66.46%
$408 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2023 9:32AM $28.290 $8.100 fallen by 71.37%
$408 NEURACTHEL manufacturing processes advance 23 Jan 2023 10:56AM $26.650 $8.100 fallen by 69.61%
$408 Technical Note - Xeroderma Pigmentosum 16 Jan 2023 9:59AM $24.600 $8.100 fallen by 67.07%
$408 afamelanotide Reduces DNA Photodamage in XP 16 Jan 2023 9:56AM $24.600 $8.100 fallen by 67.07%
$408 CLINUVEL Newsletter I - January 2023 10 Jan 2023 10:57AM $23.630 $8.100 fallen by 65.72%
$408 CLINUVEL Newsletter VI - December 2022 23 Dec 2022 11:29AM $21.390 $8.100 fallen by 62.13%
$408 Notification of cessation of securities - CUV 21 Dec 2022 3:35PM $21.310 $8.100 fallen by 61.99%

251 - 275 of 876 results

Page 11 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.